SHR-A2102 is a NECTIN4-targeting ADC with a cleavable linker and a topoisomerase I inhibitor (TOP1i) payload that led to an ORR of 38% (28/73) in urothelial cancer patients in a phase I clinical trial in solid tumor patients (NCT05735275) (Tang et al., 2025), and ORRs of 60% (31/52), 50% (6/12) and 33.1% (52/157) in breast cancer, HNC and NSCLC patients, respectively, in another phase I clinical trial (NCT05701709) (Zhong R. et al., 2025). This evidence concerns the gene NECTIN4 and non-small cell lung carcinoma.